NYSE · Healthcare · Drug Manufacturers - General · Denmark
Novo Nordisk ADR is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - General industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Novo Nordisk ADR stock.
Undervalued: intrinsic value $78.79 per share, market price $38.42, margin of safety 51.2% (as of 2026-10-19).
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $78.79; the price of $38.42 is 51% below that value, and 77% of that value comes from beyond year five.
Leak Score: 79/100 on 10 of 12 signals (Clear Leak).
8 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
NVO is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $78.79; the price of $38.42 is 51% below that value, and 77% of that value comes from beyond year five.
$78.79 per share (as of the 2026-10-19 close), against a market price of $38.42. That is a margin of safety of 51.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for less growth than the company has already delivered. Repeating its past would be enough. Yearly sales decline the price allows: 5.4%. Yearly sales growth it has sustained: 13.6%.
79 out of 100, which we rate "Clear Leak", on 10 of 12 value investing signals.